Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 30/100

INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Key Takeaway: ClaimsFiler has alerted Invivyd, Inc. shareholders about a class action lawsuit regarding the company's failure to disclose critical information about its COVID-19 treatment, ADG20. The lawsuit is focused on the period between November 29 to December 14, 2021, when significant efficacy issues against the Omicron variant were revealed. Following the disclosure of these test results, Invivyd's stock price experienced a sharp decline. Investors have until April 3, 2023, to file lead plaintiff applications.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company's stock price dropped nearly 80% after disappointing test results.
  • Shareholders are reminded of the impending deadline for a class action lawsuit.
  • Invivyd executives are accused of failing to disclose material information regarding product efficacy.

Full Press Release Details

NEW ORLEANS, March 14, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s shares between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Invivyd investors should visit us at https://claimsfiler.com/cases/nasdaq-ivvd/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline to file lead plaintiff applications is April 3, 2023.

Which company is involved in the securities class action?

The case involves Invivyd, Inc., formerly known as Adagio Therapeutics, Inc.

What caused shares of Adagio to drop significantly?

Shares plummeted after Adagio revealed that ADG20 was much less effective against Omicron.

How can investors get more information about the case?

Investors can visit https://claimsfiler.com/cases/nasdaq-ivvd/ or call 844-367-9658.

What law firm is associated with this case?

Kahn Swick & Foti, LLC is the law firm available for legal discussions.

Last updated: Mar 15, 2023